Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 1998

View Archived Issues

An overview of antiviral intervention strategies for HIV therapy

Lysostaphin: effective in rabbits with aortic valve endocarditis due to MRSA

Chiron updates HIV product development

NeoPharm scales up IL13-PE38QQR manufacturing

Findings on Atlantic's 2-5A antisense compound targeting telomerase published

New nonfeminizing estrogens with radical-scavenging activity

IL-4 fusion toxin shows potent antitumor activity in murine model of KS

Enzo discovery paves the way for antisense therapy of AIDS

Anti-HIV peptide T-22 acts as a CXCR4 receptor antagonist

AMD-3100: a potent chemokine CXCR4 antagonist enters clinical testing

French group develops new inhibitors of HIV-1 protease dimerization

Anti-HIV activity demonstrated for Teijin's antioxidant

Dong-A carbapenem undergoes pharmacokinetic evaluation in rats

Magainin publishes preclinical data for squalamine

European marketing application submitted for RenaGel

Gene Logic to acquire OncorMed

Allergan signs collaborative agreement with Santen for brimonidine

FDA grants fast track status to Miravant's Purlytin

New hormonal agents discovered by Ligand

GABA-A receptor modulators discovered by NeuroSearch

Dermatological agents in development at Galderma

Novartis presents new protein kinase inhibitors for cancer, psoriasis

Korean investigators design effective and safe agents for HBV

Intensive therapy for type I diabetes may increase cardiovascular disease risk

VALUE study now under way in Canada

AIDS vaccine combination is safe and immunogenic in seronegative volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...